What is RETINALGENIX TECHNOLOGIES INC's earnings per share (EPS)?

RETINALGENIX TECHNOLOGIES INC (RTGN) reported diluted earnings per share of $-0.13 for fiscal year 2025. This represents a 45.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

RETINALGENIX TECHNOLOGIES INC Financials

RTGN

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows RETINALGENIX TECHNOLOGIES INC (RTGN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 0/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of RETINALGENIX TECHNOLOGIES INC's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Liquidity

RETINALGENIX TECHNOLOGIES INC's current ratio of 0.01 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

N/A

EPS (Diluted)

$-0.13

YoY+45.8%

RETINALGENIX TECHNOLOGIES INC earned $-0.13 per diluted share (EPS) in fiscal year 2025. This represents an increase of 45.8% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$15K

YoY+143.8%

5Y CAGR+46.1%

RETINALGENIX TECHNOLOGIES INC held $15K in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

19M

YoY+1.3%

5Y CAGR-14.3%

RETINALGENIX TECHNOLOGIES INC had 19M shares outstanding in fiscal year 2025. This represents an increase of 1.3% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

$83K

RETINALGENIX TECHNOLOGIES INC invested $83K in research and development in fiscal year 2025.

Share Buybacks

N/A

Capital Expenditures

N/A

RTGN Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$83K	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	$4K0.0%	$4K	N/A	N/A	$3K	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	$-0.13+45.8%	$-0.24-100.0%	$-0.12+52.0%	$-0.25	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$20K+41.7%	$14K+9.2%	$13K	N/A	$103K+24.2%	$83K-0.2%	$83K
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	$244K-33.8%	$369K	N/A
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	$9600.0%	$9600.0%	$960	N/A	$9600.0%	$9600.0%	$960
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	N/A	$-0.03+11.8%	$-0.03-13.3%	$-0.03	N/A	$-0.040.0%	$-0.04+66.7%	$-0.12

RTGN Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$21K+40.8%	$15K+9480.8%	$156-46.9%	$294-94.1%	$5K-91.9%	$61K
Current Assets	$15K+143.8%	$6K	$0-100.0%	$38-99.2%	$5K-91.9%	$61K
Cash & Equivalents	$15K+143.8%	$6K	$0-100.0%	$38-99.2%	$5K+122.9%	$2K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.3M+57.3%	$1.5M+5.1%	$1.4M+31.5%	$1.1M+127.7%	$470K+232.1%	$141K
Current Liabilities	$2.3M+57.7%	$1.5M+4.6%	$1.4M	N/A	N/A	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$2.3M-57.4%	-$1.5M-4.1%	-$1.4M-31.5%	-$1.1M-130.1%	-$465K-478.3%	-$80K
Retained Earnings	-$17.9M-15.7%	-$15.4M-38.9%	-$11.1M-23.2%	-$9.0M-76.7%	-$5.1M-74.5%	-$2.9M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$21K+200.5%	$7K-16.5%	$8K-29.7%	$12K-20.2%	$15K-83.2%	$89K+2.1%	$87K+72.3%	$51K
Current Assets	$15K+15958.7%	$92-89.0%	$839-77.4%	$4K-38.8%	$6K-92.3%	$79K-9.0%	$87K+72.5%	$50K
Cash & Equivalents	$15K+15958.7%	$92-89.0%	$839-77.4%	$4K-38.8%	$6K-92.3%	$79K-9.0%	$87K+72.5%	$50K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.3M+6.6%	$2.2M+9.6%	$2.0M+18.4%	$1.7M+13.7%	$1.5M-24.0%	$1.9M+2.4%	$1.9M+21.0%	$1.6M
Current Liabilities	$2.3M+6.7%	$2.2M+9.6%	$2.0M+18.5%	$1.7M+13.8%	$1.5M-24.0%	$1.9M	N/A	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$2.3M-6.0%	-$2.2M-9.7%	-$2.0M-18.8%	-$1.7M-14.0%	-$1.5M+21.1%	-$1.9M-2.4%	-$1.8M-19.3%	-$1.5M
Retained Earnings	-$17.9M-3.6%	-$17.2M-3.4%	-$16.7M-4.1%	-$16.0M-3.8%	-$15.4M-6.0%	-$14.6M-4.6%	-$13.9M-5.0%	-$13.3M

RTGN Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	N/A	N/A	N/A	N/A	N/A
Current Ratio	0.010.0	0.000.0	0.00	N/A	N/A	N/A
Debt-to-Equity	-1.010.0	-1.01-0.0	-1.000.0	-1.00+0.0	-1.01+0.7	-1.76
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Current Ratio	0.010.0	0.000.0	0.000.0	0.000.0	0.00-0.0	0.04	N/A	N/A
Debt-to-Equity	-1.010.0	-1.000.0	-1.000.0	-1.010.0	-1.01+0.0	-1.050.0	-1.05-0.0	-1.03
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$2.3M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.01), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

QT Imaging Holdings QTIH

$64.5M

Positron POSC

$62.5M

Cannabix Technol BLOZF

$65.8M

Acarix AB ACIXF

$40.8M

Frequently Asked Questions

What are RETINALGENIX TECHNOLOGIES INC's total assets?

RETINALGENIX TECHNOLOGIES INC (RTGN) had $21K in total assets as of fiscal year 2025, including both current and long-term assets.

How much does RETINALGENIX TECHNOLOGIES INC spend on research and development?

RETINALGENIX TECHNOLOGIES INC (RTGN) invested $83K in research and development during fiscal year 2025.

How many shares does RETINALGENIX TECHNOLOGIES INC have outstanding?

RETINALGENIX TECHNOLOGIES INC (RTGN) had 19M shares outstanding as of fiscal year 2025.

What is RETINALGENIX TECHNOLOGIES INC's current ratio?

RETINALGENIX TECHNOLOGIES INC (RTGN) had a current ratio of 0.01 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is RETINALGENIX TECHNOLOGIES INC's debt-to-equity ratio?

RETINALGENIX TECHNOLOGIES INC (RTGN) had a debt-to-equity ratio of -1.01 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Why is RETINALGENIX TECHNOLOGIES INC's debt-to-equity ratio negative or unusual?

RETINALGENIX TECHNOLOGIES INC (RTGN) has negative shareholder equity of -$2.3M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

How financially healthy is RETINALGENIX TECHNOLOGIES INC?

RETINALGENIX TECHNOLOGIES INC (RTGN) scores 0 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.